ANGPTL3 and hypertriglyceridemia: In a phase IIb trial, administration of vupanorsen, an ASO targeting hepatic ANGPTL3, to patients with hypercholesterolemia and hypertriglyceridemia significantly reduced triglycerides together with a modest decrease in LDL-cholesterol.